US equities |
NVDA $238.78 ▲+2.06% SPCX $170.97 ▲+7.55% MU $1,063.42 ▼-1.07% TSLA $378.76 ▲+2.21% SNDK $1,704.55 ▼-0.90% MSFT $525.01 ▲+1.45% INTC $116.19 ▼-2.63% META $741.88 ▲+1.89%
FinancialContent

Articles published by Mural Oncology, Inc.

News headline image
Mural Oncology Announces Plans to Explore Strategic Alternatives
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology to Participate in Two Upcoming Investor Conferences
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology to Present at Two Upcoming Investor Conferences
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mural Oncology, Inc.
Via GlobeNewswire
Tickers MURA